Eindhoven Cancer Registry, Comprehensive Cancer Centre South, Eindhoven, The Netherlands.
Eur J Surg Oncol. 2010 Feb;36(2):135-40. doi: 10.1016/j.ejso.2009.05.012. Epub 2009 Jul 2.
The aim was to investigate whether a set of measures directed at increasing lymph node (LN) detection among colon cancer patients led to clinically relevant changes in LN detection rate.
Data of all patients with curative colon cancer (pT(any) N(any) M0) diagnosed in 1999-2007 whose resection specimens were evaluated by the Institute for Pathology and Medical Microbiology in Eindhoven (n=1501) were included. Feedback to specialists, increased fixation time, and ex-vivo injection of the specimen with Patent blue V dye were used to increase LN detection rate. Trends in the proportion of patients with insufficient LNs examined were investigated; moreover, the Patent blue-stained patients (n=86) were compared with a group of unstained patients (n=84). Based on the decrease in the proportion of high-risk node-negative patients, a calculation of chemotherapy-related costs saved was made.
The proportion of patients with <12 LNs examined decreased from 87% in 1999 to 48% in 2007 (p(trend)<0.0001). In the stained group this was 37%, versus 56% for the unstained group (p=0.010). In 1999, 79% of stage II patients were high-risk compared to 55% in 2007, which translates to a saving of almost 1,000,000 euro based on 92 stage II patients diagnosed in 2007.
A diverse set of measures increased the number of examined lymph nodes among patients with colon cancer. Large savings can be made due to the reduced proportion of high-risk node-negative patients who would otherwise have received adjuvant chemotherapy.
本研究旨在探讨一组旨在提高结肠癌患者淋巴结(LN)检出率的措施是否能导致 LN 检出率的临床相关变化。
纳入了 1999-2007 年间在埃因霍温病理与医学微生物学研究所(Institute for Pathology and Medical Microbiology in Eindhoven)评估的所有接受根治性结肠癌(pT(任何)N(任何)M0)治疗的患者(n=1501)的资料。为提高 LN 检出率,采用了向专科医生反馈信息、延长固定时间以及对标本进行专利蓝 V 染料离体注射等措施。我们对 LN 检查不足患者的比例趋势进行了研究;此外,我们还对专利蓝染色组(n=86)和非染色组(n=84)进行了比较。根据高危淋巴结阴性患者比例的降低,计算了节省的化疗相关费用。
接受<12 枚淋巴结检查的患者比例从 1999 年的 87%降至 2007 年的 48%(p(趋势)<0.0001)。在染色组中,这一比例为 37%,而非染色组为 56%(p=0.010)。1999 年,79%的 II 期患者为高危患者,而 2007 年这一比例为 55%,这意味着基于 2007 年诊断的 92 例 II 期患者,节省了近 100 万欧元。
采用了一系列不同的措施提高了结肠癌患者的淋巴结检查数量。由于减少了接受辅助化疗的高危淋巴结阴性患者的比例,从而可以节省大量费用。